

## Information Regarding Clinical Trial

<b>Title</b>	A phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy +/- one year of everolimus in patients with high risk hormone receptor positive HER-2 negative breast cancer. Breast cancer therapy evaluating everolimus with endocrine therapy
<b>Protocol Number</b>	S1207
<b>Sponsor</b>	SWOG
<b>Investigator</b>	J. Thaddeus Beck, MD 3232 N. North Hills Blvd. Fayetteville, AR 72703
<b>Study Related Phone Numbers</b>	479-587-1700 (24 hours)
<b>Key Points for Study</b>	With positive estrogen and/or progesterone receptor status and negative HER-2 Completion of chemotherapy Completed either breast conserving surgery or total mastectomy Must be registered no sooner than 21 days after completion of radiation therapy. Must not receive trastuzumab or have prior exposure to mTOR inhibitors <b>Patient must have had chemotherapy to be eligible</b>